Role of apoptosis resistance in immune evasion and metastasis of colorectal cancer

被引:22
作者
Liu, Kebin [1 ]
机构
[1] Georgia Hlth Sci Univ, Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA 30912 USA
关键词
Apoptosis; Fas; Metastasis; Immune evasion;
D O I
10.4251/wjgo.v2.i11.399
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The host immune system functions as a guardian against tumor development. It has been demonstrated that cytotoxic T lymphocyte (CTL)-mediated cytotoxic pathways function to inhibit or delay human colorectal cancer development. However, the host anti-tumor immune responses also 'edit' the tumor and select for more aggressive variants, resulting in immune evasion and tumor escape. Fas is a death receptor that mediates one of the major cytotoxic effector mechanisms of the CTLs. Fas is highly expressed in normal human colon epithelial cells but is frequently silenced in colorectal carcinoma, especially in metastatic colorectal carcinoma, suggesting that loss of Fas expression and function may be an immune evasion and tumor escape mechanism. In addition, recent studies indicated that Fas also mediates cellular proliferation signaling pathways to promote tumor development. Therefore, the death receptor Fas may not only transduce death signals to suppress tumor development but also activate cellular proliferation and the migration process to promote tumor growth and progression. Thus, understanding the mechanisms by which the Fas receptor and its associated protein complex transduces the death and survival signals may identify molecular targets for the development of therapeutic strategy to enhance the Fas-mediated death signals to increase the efficacy of cancer immunotherapy. (C) 2010 Baishideng. All rights reserved.
引用
收藏
页码:399 / 406
页数:8
相关论文
共 85 条
[1]   A multi-functional role of interferon regulatory factor-8 in solid tumor and myeloid cell biology [J].
Abrams, Scott I. .
IMMUNOLOGIC RESEARCH, 2010, 46 (1-3) :59-71
[2]   CD95 ligand induces motility and invasiveness of apoptosis-resistant tumor cells [J].
Barnhart, BC ;
Legembre, P ;
Pietras, E ;
Bubici, C ;
Franzoso, G ;
Peter, ME .
EMBO JOURNAL, 2004, 23 (15) :3175-3185
[3]   CD95 ligand-expressing tumors are rejected in anti-tumor TCR transgenic perforin knockout mice [J].
Behrens, CK ;
Igney, FH ;
Arnold, B ;
Möller, P ;
Krammer, PH .
JOURNAL OF IMMUNOLOGY, 2001, 166 (05) :3240-3247
[4]  
Bennett MW, 1998, J IMMUNOL, V160, P5669
[5]   Differential role of Fas/Fas ligand interactions in cytolysis of primary and metastatic colon carcinoma cell lines by human antigen-specific CD8+ CTL [J].
Bergmann-Leitner, ES ;
Abrams, SI .
JOURNAL OF IMMUNOLOGY, 2000, 164 (09) :4941-4954
[6]   CANCER RISK AFTER RENAL-TRANSPLANTATION IN THE NORDIC COUNTRIES, 1964-1986 [J].
BIRKELAND, SA ;
STORM, HH ;
LAMM, LU ;
BARLOW, L ;
BLOHME, I ;
FORSBERG, B ;
EKLUND, B ;
FJELDBORG, O ;
FRIEDBERG, M ;
FRODIN, L ;
GLATTRE, E ;
HALVORSEN, S ;
HOLM, NV ;
JAKOBSEN, A ;
JORGENSEN, HE ;
LADEFOGED, J ;
LINDHOLM, T ;
LUNDGREN, G ;
PUKKALA, E .
INTERNATIONAL JOURNAL OF CANCER, 1995, 60 (02) :183-189
[7]   Human T cell responses against melanoma [J].
Boon, Thierry ;
Coulie, Pierre G. ;
Van den Eynde, Benoit J. ;
van der Bruggen, Pierre .
ANNUAL REVIEW OF IMMUNOLOGY, 2006, 24 :175-208
[8]   Aids-related malignancies [J].
Boshoff, C ;
Weiss, R .
NATURE REVIEWS CANCER, 2002, 2 (05) :373-382
[9]   The Fas/Fas ligand pathway is important for optimal tumor regression in a mouse model of CTL adoptive immunotherapy of experimental CMS4 lung metastases [J].
Caldwell, SA ;
Ryan, MH ;
McDuffie, E ;
Abrams, SI .
JOURNAL OF IMMUNOLOGY, 2003, 171 (05) :2402-2412
[10]   Coordination of Intratumoral Immune Reaction and Human Colorectal Cancer Recurrence [J].
Camus, Matthieu ;
Tosolini, Marie ;
Mlecnik, Bernhard ;
Pages, Franck ;
Kirilovsky, Amos ;
Berger, Anne ;
Costes, Anne ;
Bindea, Gabriela ;
Charoentong, Pornpimol ;
Bruneval, Patrick ;
Trajanoski, Zlatko ;
Fridman, Wolf-Herman ;
Galon, Jerome .
CANCER RESEARCH, 2009, 69 (06) :2685-2693